VivoSeq
Other

Atrophy

53

Pipeline Programs↗

9

Active Trials↗

30

Companies Involved↗

Atrophy is a moderately active landscape with 53 programs across 30 companies. The most active players are LEO Pharma, Biogen, Quark Pharmaceuticals. 13 therapies are approved with 14 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

61/100

Pipeline Velocity

15/100

Mech. Concentration

15/100

Completion Rate

88/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

LEO Pharma logo

LEO Pharma

3 programs

Phase 1Biogen logo

Biogen

1 program

Phase 1Q

Quark Pharmaceuticals

1 program

Phase 1Novartis logo

Novartis

1 program

Phase 2I

ITF Research Pharma, S.L.U.

1 program

Phase 2Akero Therapeutics logo

Akero Therapeutics

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Trial Status

78

clinical trials

Completed57 · 73%
Recruiting6 · 8%
Terminated4 · 5%
Withdrawn4 · 5%
Unknown status4 · 5%
Not yet recruiting3 · 4%

Clinical Trials

Trial Activity

78 trials

Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg "All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)"
Recruiting·Takeda logoTakeda·N/A·NCT03555578·1,890 enrolled
Clinical Trial of Mexiletine Hydrochloride for Spinal and Bulbar Muscular Atrophy
Recruiting·—·Phase 2/3·NCT06862596·68 enrolled
Treatment of Vaginal Atrophy With Low Intensity Nanosecond Neodymium Laser
Recruiting·MMeLSyTech, Ltd·N/A·NCT05335317·120 enrolled
A Placebo-controlled Study of Clenbuterol in Spinal and Bulbar Muscular Atrophy
Recruiting·—·Phase 2·NCT06169046·90 enrolled
Assessment of Three-Dimensional Bone Augmentation of Severely Atrophied Posterior Mandibular Alveolar Ridges Using Customized-3D Zirconia Barriers Versus Pre-bent Titanium Mesh: A Randomized Controlled Clinical Trial
Recruiting·—·Preclinical·NCT07700095·16 enrolled
Testing Personalized High Definition Transcranial Direct Current Stimulation (HD-tDCS) as a Treatment of Posterior Cortical Atrophy
Recruiting·UUniversity of Michigan·Preclinical·NCT07191327·50 enrolled
The Efficacy of Topical Vaginal Oxytocin Gel in Postmenopausal Women With Vulvovaginal Atrophy
Not yet recruiting·OOxagon·Phase 3·NCT06514586·244 enrolled
Metformin and Muscle Recovery Following ACL Surgery
Not yet recruiting·UUniversity of Utah·Phase 1·NCT07699367·40 enrolled
Assessment of Bone Density Following Application of Bone Marrow Aspirate Concentrate Around Zygomatic Implants (Via the Intrasinus Approach): A Case Series Study
Not yet recruiting·CCairo University·Preclinical·NCT07657026·10 enrolled
Topical DHEA Against Vaginal Atrophy
Completed·EEndoCeutics Inc.·Phase 3·NCT01846442·218 enrolled
Safety & Efficacy WC3011 (Estradiol Vaginal Cream) in the Treatment of Vulvovaginal Atrophy in Postmenopausal Women
Completed·—·Phase 3·NCT01400776·722 enrolled
A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women
Completed·Shionogi logoShionogi·Phase 3·NCT00276094·826 enrolled
Interest of Topical Spironolactone's Administration to Prevent Corticoid-induced Epidermal Atrophy
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT01407471·26 enrolled
Visnadine, Prenylflavonoids and Bovine Colostrum to Treat Vulvovaginal Atrophy in Postmenopausal Women
Completed·UUniversity of Messina·Phase 2·NCT03281655·54 enrolled
Study to Determine Efficacy & Safety of a Low Concentration Estriol (0.005%) in Postmenopausal Vaginal Atrophy.
Completed·IItalfarmaco S.A·Phase 3·NCT04574999·167 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)